There are currently 193 active clinical trials seeking participants for Colorectal Cancer research studies. The states with the highest number of trials for Colorectal Cancer participants are California, Illinois, Ohio and New York.
TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
NCT05343013
Recruiting
To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Colorectal Cancer
Register for Updates
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
NCT05957367
Recruiting
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of DCC-3116 with other anticancer agents.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California +7 locations
Conditions: Colorectal Cancer, GIST
Register for Updates
A Study of CDX-585 in Patients With Advanced Malignancies
NCT05788484
Recruiting
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: George Washington University Cancer Center, Washington, District of Columbia +3 locations
Conditions: Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
Register for Updates
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
NCT04157985
Recruiting
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
Register for Updates
Real-time Computer-Aided Detection of Colonic Adenomas With NEC WISE VISION® Endoscopy
NCT05611151
Recruiting
This is a prospective, multicenter, randomized study to evaluate the clinical performance of a novel CADe device, WISE VISION® Endoscopy System, in patients undergoing high-definition white light (HDWL) colonoscopy for screening or surveillance of colorectal Cancer (CRC). Eligible subjects who meet the study inclusion/exclusion criteria will be randomized in a 1:1 ratio to undergo colonoscopy : Experimental: CADe colonoscopy procedure with WISE VISION® Endoscopy (CADe Group) Control: Standard... Read More
Gender:
All
Ages:
Between 45 years and 75 years
Trial Updated:
03/19/2024
Locations: Kansas City VA Hospital, Kansas City, Missouri +4 locations
Conditions: Colorectal Cancer, Adenoma Colon, Polyp of Colon
Register for Updates
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264
Recruiting
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Honor Health, Scottsdale, Arizona +7 locations
Conditions: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Gastroesophageal-junction Cancer, WNT Pathway, β-catenin, Beta-catenin, Adenomatous Polyposis Coli, APC
Register for Updates
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT05425940
Recruiting
This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 + atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Exelixis Clinical Site #65, Jonesboro, Alabama +132 locations
Conditions: Colorectal Cancer
Register for Updates
Stage II/III Colorectal Cancer Recurrence
NCT06314958
Recruiting
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: City of Hope Medical Center, Monrovia, California +3 locations
Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Recurrent
Register for Updates
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
NCT06314971
Recruiting
Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC. This study seeks to improve the prediction of recurrence-free survival in individuals who have survived T1 CRC.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: City of Hope Medical Center, Duarte, California +2 locations
Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I, Colorectal Neoplasms Malignant, Colorectal Cancer Recurrent
Register for Updates
Walnuts and Colon Health
NCT05195970
Recruiting
The purpose of this research study is to examine whether adding walnuts to your diet can have a beneficial effect on the gut bacteria population, inflammatory markers in the blood, and the tissue that lines the inside of the colon.
Gender:
All
Ages:
Between 39 years and 75 years
Trial Updated:
03/15/2024
Locations: UConn Health, Farmington, Connecticut +1 locations
Conditions: Colorectal Cancer, Diet Habit
Register for Updates
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
Recruiting
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: START Midwest, Grand Rapids, Michigan +1 locations
Conditions: Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer
Register for Updates
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
NCT03366155
Recruiting
Background: Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective. A device that does this a pump that delivers drugs over 2 weeks at constant rate into the hepatic artery. The person s body temperature causes the drug to flow from the pump. Researchers want to see if this helps people with colorectal metastases to the liver. Objective: To study the effectiveness of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases, Colorectal Carcinoma
Register for Updates